Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 9/20 | 0.76 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.76 |
| ▸ | KDR | P35968 | 7/20 | 0.75 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.75 |
| ▸ | RET | P07949 | 3/20 | 0.75 |
| ▸ | PLK4 | O00444 | 2/20 | 0.75 |
| ▸ | AURKA | O14965 | 2/20 | 0.75 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.75 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.75 |
| ▸ | ABL1 | P00519 | 2/20 | 0.75 |
| ▸ | LCK | P06239 | 2/20 | 0.75 |
| ▸ | FYN | P06241 | 2/20 | 0.75 |
| ▸ | LYN | P07948 | 2/20 | 0.75 |
| ▸ | SRC | P12931 | 2/20 | 0.75 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.75 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.75 |
| ▸ | AXL | P30530 | 2/20 | 0.75 |
| ▸ | FRK | P42685 | 2/20 | 0.75 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.75 |
| ▸ | BLK | P51451 | 2/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL257980 | 0.95 | RAF1 (0.82) | RAF1EPHX2KDRMAPK14RET | |
| SCHEMBL14453650 | 0.92 | KDR (0.70) | RAF1EPHX2KDRMAPK14RET | |
| SCHEMBL1532339 | 0.91 | RAF1 (0.77) | RAF1EPHX2KDRMAPK14RET | |
| SCHEMBL10163311 | 0.90 | RAF1 (0.76) | RAF1EPHX2KDRMAPK14RET | |
| SCHEMBL5569372 | 0.90 | KDR (0.74) | RAF1EPHX2KDRMAPK14RET | |
| SCHEMBL28430251 | 0.89 | RAF1 (0.78) | RAF1EPHX2KDRMAPK14RET | |
| SCHEMBL19878522 | 0.89 | KDR (0.74) | RAF1EPHX2KDRMAPK14RET | |
| SCHEMBL19888730 | 0.89 | RAF1 (0.78) | RAF1EPHX2KDRMAPK14RET | |
| SCHEMBL16620832 | 0.89 | RAF1 (0.74) | RAF1EPHX2KDRMAPK14RET | |
| SCHEMBL16628069 | 0.89 | KDR (0.73) | RAF1EPHX2KDRMAPK14RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3500257-B1 | KINASE INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF TREATING CANCER | ICAHN SCHOOL MED MOUNT SINAI (US) | 2025-07-02 | — | — | EP | disclosed |
| US-12187696-B2 | Urea motif containing compounds and derivatives thereof as antibacterial drugs | Technische Universität München (DE) | 2025-01-07 | — | — | US | disclosed |
| EP-3464260-B1 | UREA MOTIF CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS ANTIBACTERIAL DRUGS | UNIV MUENCHEN TECH (DE) | 2021-10-27 | — | — | EP | disclosed |
| EP-3464260-B1 | UREA MOTIF CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS ANTIBACTERIAL DRUGS | UNIV MUENCHEN TECH (DE) | 2021-10-27 | — | — | EP | disclosed |
| US-11066370-B2 | Kinase inhibitor compounds, compositions, and methods of treating cancer | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2021-07-20 | — | — | US | disclosed |
| US-11066370-B2 | Kinase inhibitor compounds, compositions, and methods of treating cancer | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2021-07-20 | — | — | US | disclosed |
| US-20210009550-A1 | UREA MOTIF CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS ANTIBACTERIAL DRUGS | Technische Universität München (DE) | 2021-01-14 | — | — | US | disclosed |
| US-20210009550-A1 | UREA MOTIF CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS ANTIBACTERIAL DRUGS | Technische Universität München (DE) | 2021-01-14 | — | — | US | disclosed |
| US-20200325103-A1 | KINASE INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF TREATING CANCER | ICAHN SCHOOL MED MOUNT SINAI (US) | 2020-10-15 | — | — | US | disclosed |
| US-20200325103-A1 | KINASE INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF TREATING CANCER | ICAHN SCHOOL MED MOUNT SINAI (US) | 2020-10-15 | — | — | US | disclosed |
| EP-3500257-A1 | KINASE INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF TREATING CANCER | Icahn School of Medicine at Mount Sinai (US) | 2019-06-26 | — | — | EP | disclosed |
| WO-2018035346-A1 | KINASE INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF TREATING CANCER | ICHAN SCHOOL OF MEDICINE AT MOUNT SINAL (US) | 2018-02-22 | — | — | WO | disclosed |
| WO-2018035346-A1 | KINASE INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF TREATING CANCER | ICHAN SCHOOL OF MEDICINE AT MOUNT SINAL (US) | 2018-02-22 | — | — | WO | disclosed |
| WO-2015051149-A1 | SORAFENIB ANALOGS AND USES THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2015-04-09 | — | — | WO | disclosed |
| US-8003657-B2 | Heterocyclic substituted bisarylurea derivatives | MERCK PATENT GMBH (DE) | 2011-08-23 | — | — | US | disclosed |
| US-20090215799-A1 | HETEROCYCLIC SUBSTITUTED BISARYLUREA DERIVATIVES | MERCK PATENT GMBH | 2009-08-27 | — | — | US | disclosed |
| US-20090124633-A1 | N-OXIDES OF HETEROCYCLIC SUBSTITUTED BISARYLUREAS FOR TREATING KINASE-MEDIATED DISEASES | MERCK PATENT GESELLSCHAFT (DE) | 2009-05-14 | — | — | US | disclosed |
| US-20080255155-A1 | KINASE INHIBITORS AND USES THEREOF | METHLYGENE INC. (CA) | 2008-10-16 | — | — | US | disclosed |
| US-20080255155-A1 | KINASE INHIBITORS AND USES THEREOF | METHLYGENE INC. (CA) | 2008-10-16 | — | — | US | disclosed |
| US-20070161677-A1 | Bisarylurea derivatives | MERCK PATENT GMBH (DE) | 2007-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200325103-A1 | KINASE INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF TREATING CANCER | MAP3K1, KSR1, MAP3K11 | RAF1 16/4885EPHX2 2634/4885KDR 706/4885 |
| US-20070161677-A1 | Bisarylurea derivatives | BRAF, RAF1, NRAS | RAF1 2/4885EPHX2 1462/4885KDR 532/4885 |
| US-11066370-B2 | Kinase inhibitor compounds, compositions, and methods of treating cancer | MAP3K1, KSR1, MAP3K11 | RAF1 16/4885EPHX2 2634/4885KDR 706/4885 |
| US-20090124633-A1 | N-OXIDES OF HETEROCYCLIC SUBSTITUTED BISARYLUREAS FOR TREATING KINASE-MEDIATED DISEASES | ABL1, NME2, MAP3K1 | RAF1 49/4885EPHX2 1010/4885KDR 993/4885 |
| US-20080255155-A1 | KINASE INHIBITORS AND USES THEREOF | ABL1, MAP3K20, MAP3K1 | RAF1 104/4885EPHX2 2019/4885KDR 746/4885 |
| US-20090215799-A1 | HETEROCYCLIC SUBSTITUTED BISARYLUREA DERIVATIVES | ABL1, BTK, PRKACA | RAF1 23/4885EPHX2 1805/4885KDR 967/4885 |
| US-20210009550-A1 | UREA MOTIF CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS ANTIBACTERIAL DRUGS | UMPS, UNG, UFM1 | RAF1 983/4885EPHX2 2615/4885KDR 3399/4885 |
| US-12187696-B2 | Urea motif containing compounds and derivatives thereof as antibacterial drugs | UMPS, UNG, UFM1 | RAF1 983/4885EPHX2 2615/4885KDR 3399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.